Oral Proteins And Peptides Market Expected To Reach $4.26 Billion By 2030 As Growth Accelerates At 22.2% CAGR
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Oral Proteins And Peptides Market Revenue Growth Supported By A CAGR Of 4.26% Through 2030
Over the recent period, the market for oral proteins and peptides has experienced rapid expansion. Projected to rise from $1.56 billion in 2025 to $1.91 billion in 2026, it is expected to achieve a compound annual growth rate (CAGR) of 22.5%. This historical growth has been driven by factors such as the restricted oral bioavailability of proteins and peptides, a heavy dependence on injectable delivery methods, an increasing incidence of diabetes and gastrointestinal conditions, heightened research efforts in peptide therapeutics, and the granting of regulatory approvals for early-stage oral peptide medications.
The oral proteins and peptides market is anticipated to experience substantial expansion in the coming years. By 2030, it is projected to reach a value of $4.26 billion, reflecting a compound annual growth rate (CAGR) of 22.2%. This forecasted growth is driven by the creation of innovative delivery technologies for oral proteins, the broadening of chronic disease management initiatives, a growing preference for personalized and combination therapies, increased healthcare spending on metabolic and hormonal conditions, and the incorporation of digital adherence and monitoring systems. Key developments during this period are likely to feature the widespread use of oral insulin and other therapeutic peptides, progress in personalized medicine with targeted oral protein treatments, a heightened emphasis on therapies for gastrointestinal disorders, the broadening of oral protein solutions for diabetes and metabolic diseases, and improvements in long-lasting and combination oral protein products.
Download A Free Sample Report For Comprehensive Market Insights:
Oral Proteins And Peptides Market Growth Drivers: What Factors Are Accelerating Expansion?
The expansion of the biopharmaceutical sector is anticipated to drive forward the oral proteins and peptides market. This sector, a subset of the wider pharmaceutical industry, is dedicated to creating, manufacturing, and marketing drugs sourced from biological materials. Its growth is fueled by innovations in biotechnology, a heightened demand for tailored medical treatments, a rising incidence of chronic illnesses, and increased funding for research and development. Oral proteins and peptides within biopharmaceuticals present a means for non-invasive drug delivery, boosting patient adherence and minimizing the reliance on injections. These compounds can address particular diseases, offering improved stability and absorption within the gastrointestinal tract. To illustrate, according to the Bioscience and Health Technology Sector, a UK governmental statistics body, in October 2025, the UK life sciences field contained 6,170 businesses out of 7,320 companies during 2023/2024. These enterprises employed 359,600 individuals and produced a turnover of £146.9 billion ($169.69 billion). Consequently, the flourishing biopharmaceutical industry is propelling the oral proteins and peptides market forward.
Oral Proteins And Peptides Market Segment Landscape And Growth Potential
The oral proteins and peptides market covered in this report is segmented –
1) By Drug Type: Linaclotide, Calcitonin, Insulin, Plecanatide, Octreotide
2) By Biological Target: Guanylate Cyclase-C (GC-C), Insulin Receptor, Other Biological Targets
3) By Mechanism Of Action: Receptor Stimulation, Substrate Degradation, Other Mechanisms Of Action
4) By Application: Gastrointestinal Disorders, Bone Disease, Neurological Disorders, Diabetes, Metabolic Disorders, Hormonal Disorder, Cancer
Subsegments:
1) By Linaclotide: Indications For Irritable Bowel Syndrome (IBS), Indications For Chronic Idiopathic Constipation (CIC)
2) By Calcitonin: Calcitonin-Salmon, Synthetic Calcitonin, Calcitonin for Osteoporosis Treatment
3) By Insulin: Long-Acting Insulin, Combination Insulin Products, Oral Insulin Formulations
4) By Plecanatide: Indications For Chronic Idiopathic Constipation (CIC), Indications For Irritable Bowel Syndrome With Constipation (IBS-C)
5) By Octreotide: Long-Acting Octreotide Formulations, Short-Acting Octreotide Formulations, Indications For Acromegaly And Neuroendocrine Tumors
Oral Proteins And Peptides Market Trends: What Is Shaping Future Industry Growth?
Leading enterprises in the oral proteins and peptides market are prioritizing the creation of novel formulation technologies aimed at boosting peptide stability, permeability, and bioavailability within oral dosage forms. These efforts strive to overcome persistent obstacles like enzymatic breakdown and insufficient absorption in the gastrointestinal tract. As an example, in August 2025, BioMed X, a biomedical research institute headquartered in Germany, initiated a new partnership with Novo Nordisk, a pharmaceutical company based in Denmark, designed to expedite progress in next-generation oral peptide delivery technologies. Through this collaboration, fresh molecular strategies and delivery mechanisms are being investigated to facilitate the development of safe, effective, and patient-friendly oral peptide therapeutics. By merging BioMed X’s early-stage research strengths with Novo Nordisk’s proficiency in peptide-based drugs, this alliance seeks to propel groundbreaking oral drug delivery methods forward and broaden the application of peptide therapies for metabolic and chronic conditions.
Oral Proteins And Peptides Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the oral proteins and peptides market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Novo Nordisk A/S, Ipsen S.A., Biocon Limited, Xeris Pharmaceuticals Inc., Adocia S.A., Zealand Pharma A/S, Diabetology Ltd., Oramed Pharmaceuticals Inc., Palatin Technologies Inc., Entera Bio Ltd.
Access The Complete Oral Proteins And Peptides Market Report:
Oral Proteins And Peptides Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the oral proteins and peptides market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral proteins and peptides market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
